Shire (SHP)

 

Latest News

Broker Forecast - Liberum Capital issues a broker note on Shire PLC

Liberum Capital today upgrades its investment rating on Shire PLC (LON:SHP) to buy (from hold) and left its price target...

CHMP recommends EU marketing authorization for ADYNOVI® [Antihemophilic Factor (Recombinant), PEGylated] for adults and adolescents with Hemophilia A

YASTEST

Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and Oncology

YASTEST

Broker Forecast - Berenberg issues a broker note on Shire PLC

Berenberg today reaffirms its buy investment rating on Shire PLC (LON:SHP) and raised its price target to 6000p (from 59...

All News

DateHeadlineSource
14-11-17Broker Forecast - Liberum Capital issues a broker note on Shire PLCStockMarketWire
13-11-17CHMP recommends EU marketing authorization for ADYNOVI® [Antihemophilic Factor (Recombinant), PEGylated] for adults and adolescents with Hemophilia ARNS
10-11-17Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and OncologyRNS
06-11-17Broker Forecast - Berenberg issues a broker note on Shire PLCStockMarketWire
03-11-17Shire plc : Director/PDMR ShareholdingRNS
01-11-17Shire plc : Director/PDMR ShareholdingRNS
01-11-17Shire plc : Total voting rightsRNS
31-10-17Broker Forecast - HSBC issues a broker note on Shire PLCStockMarketWire
31-10-17Broker Forecast - Deutsche Bank issues a broker note on Shire PLCStockMarketWire
30-10-17Broker Forecast - Barclays Capital issues a broker note on Shire PLCStockMarketWire
30-10-17Broker Forecast - Citigroup issues a broker note on Shire PLCStockMarketWire
27-10-17Shire product sales, earnings up in Q3StockMarketWire
27-10-17Shire plc : 3rd Quarter ResultsRNS
26-10-17Shire Receives European Approval for Label Extension of FIRAZYR® (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Paediatric PatientsRNS
25-10-17Shire updates on SHP654 statusStockMarketWire
25-10-17Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of Hemophilia ARNS
24-10-17Broker Forecast - Liberum Capital issues a broker note on Shire PLCStockMarketWire
24-10-17Broker Forecast - Berenberg issues a broker note on Shire PLCStockMarketWire
13-10-17Shire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP Opinion in Europe for Patients with Acute Lymphoblastic Leukemia (ALL)RNS
12-10-17Broker Forecast - Morgan Stanley issues a broker note on Shire PLCStockMarketWire
12-10-17Shire plc : Notice of ResultsRNS
05-10-17Shire plc : Director/PDMR ShareholdingRNS
05-10-17Can this winning Dogs of the Footsie portfolio do it again?Interactive Investor
03-10-17Director Deals - Shire PLC (SHP)StockMarketWire
03-10-17Director Deals - Shire PLC (SHP)StockMarketWire
03-10-17Director Deals - Shire PLC (SHP)StockMarketWire
03-10-17Director Deals - Shire PLC (SHP)StockMarketWire
03-10-17Shire plc : Director/PDMR ShareholdingRNS
02-10-17Shire plc : Total voting rightsRNS
28-09-17Eight top tips for more experienced investorsInteractive Investor
22-09-17PM Brexit speech hurts the pound but lifts the FTSEStockMarketWire
20-09-17Miners drag on FTSE 100 StockMarketWire
20-09-17Shire attention deficit disorder drug meets trial results in JapanStockMarketWire
20-09-17Shire and Shionogi Announce Positive Topline Results for INTUNIV® Evaluated in Phase 3 Clinical Trial in Adults with ADHDRNS
13-09-17Broker Forecast - JP Morgan Cazenove issues a broker note on Shire PLCStockMarketWire
12-09-17Shire Receives FDA Fast Track Designation for SHP607 for the Prevention of Chronic Lung Disease in Extremely Premature InfantsRNS
11-09-17Shire plc : Elections for the interim dividend in respect of the six months to June 30, 2017RNS
11-09-17Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal TrialRNS
07-09-17Shire to participate at two upcoming investor conferencesRNS
05-09-17Broker Forecast - Deutsche Bank issues a broker note on Shire PLCStockMarketWire

RSS feeds

  • Editorial news feed for LSE:SHP Editorial
  • Regulatory news feed for LSE:SHP Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account